{"id":18449,"date":"2026-03-24T14:56:34","date_gmt":"2026-03-24T21:56:34","guid":{"rendered":"https:\/\/depts.washington.edu\/globalwach\/?p=18449"},"modified":"2026-04-01T07:13:44","modified_gmt":"2026-04-01T14:13:44","slug":"primary-results-of-the-enterics-for-global-health-efgh-study-on-shigella-burden-and-antibiotic-resistance-in-children-published-in-the-lancet-global-health","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/globalwach\/2026\/03\/24\/primary-results-of-the-enterics-for-global-health-efgh-study-on-shigella-burden-and-antibiotic-resistance-in-children-published-in-the-lancet-global-health\/","title":{"rendered":"Primary Results of the Enterics for Global Health (EFGH) Study on Shigella Burden and Antibiotic Resistance in Children Published in The Lancet Global Health"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-16429\" src=\"https:\/\/depts.washington.edu\/globalwach\/wordpress\/wp-content\/uploads\/2023\/02\/EFGH-Logo-300x227.jpg\" alt=\"\" width=\"213\" height=\"161\" srcset=\"https:\/\/depts.washington.edu\/globalwach\/wordpress\/wp-content\/uploads\/2023\/02\/EFGH-Logo-300x227.jpg 300w, https:\/\/depts.washington.edu\/globalwach\/wordpress\/wp-content\/uploads\/2023\/02\/EFGH-Logo-768x582.jpg 768w, https:\/\/depts.washington.edu\/globalwach\/wordpress\/wp-content\/uploads\/2023\/02\/EFGH-Logo-375x284.jpg 375w, https:\/\/depts.washington.edu\/globalwach\/wordpress\/wp-content\/uploads\/2023\/02\/EFGH-Logo-750x569.jpg 750w, https:\/\/depts.washington.edu\/globalwach\/wordpress\/wp-content\/uploads\/2023\/02\/EFGH-Logo-108x81.jpg 108w, https:\/\/depts.washington.edu\/globalwach\/wordpress\/wp-content\/uploads\/2023\/02\/EFGH-Logo.jpg 992w\" sizes=\"auto, (max-width: 213px) 100vw, 213px\" \/>The <a href=\"https:\/\/depts.washington.edu\/efgh\/\" target=\"_blank\" rel=\"noopener\">Enterics for Global Health (EFGH) study,<\/a> funded by the Gates Foundation, has found that <em>Shigella<\/em>\u2014a leading cause of childhood diarrhea worldwide\u2014poses a far greater threat than previously described. The study documents both a substantial disease burden in young children and rapidly increasing resistance to commonly used, and recommended, antibiotics.<\/p>\n<p>These findings, <a href=\"https:\/\/www.thelancet.com\/journals\/langlo\/article\/PIIS2214-109X(25)00534-0\/fulltext\"><strong>now published by <em>The Lancet Global Health<\/em><\/strong><\/a>, underscore the need for vaccine development and strengthened antimicrobial resistance (AMR) monitoring globally.<\/p>\n<p><!--more--><\/p>\n<p>Conducted from June 2022 to August 2024, the EFGH study enrolled 9,476 children aged 6\u201335 months with acute diarrhea across Kenya, Malawi, Mali, The Gambia, Bangladesh, Pakistan, and Peru. This large-scale, prospective surveillance effort used both microbiologic culture and quantitative PCR (qPCR) to identify <em>Shigella<\/em> infections and to measure antibiotic resistance patterns. Its hybrid design combined facility\u2011based surveillance, household population mapping, and assessment of healthcare\u2011seeking patterns also generated robust and comparable incidence estimates.<\/p>\n<p><em>Shigella<\/em> was detected in 20% of children tested by qPCR and 9.3% by culture with incidence rates ranging from 2.7-26.9 <em>Shigella <\/em>diarrhea cases per 100 child-years. High levels of antibiotic resistance were documented, including resistance to the leading WHO-recommended antibiotics for treating dysentery: Ciprofloxacin, Azithromycin, Ceftriaxone. These patterns reflect escalating AMR risks, leaving fewer effective treatment options for children in high\u2011burden settings. The study\u2019s findings arrive as potential <em>Shigella<\/em> vaccine candidates advance in development, which target the most frequently observed serotypes.<\/p>\n<p>\u201cEFGH shows how rigorous data and strong multinational partnerships can accelerate progress against diseases that disproportionately affect children,\u201d stated Dr. Patricia Pavlinac, Coordinating Primary Investigator. \u201cBut this is only the beginning. Vaccines must still be tested for safety and efficacy, antibiotic resistance must be vigilantly monitored, and treatment guidelines updated to protect children from this debilitating and all-too-common disease.\u201d<\/p>\n<p>The EFGH study also answers critical questions to eventual Shigella vaccine trial design: such as what are the optimal disease severity definitions to use to capture the most vaccine preventable forms of <em>Shigella <\/em>disease and what sample types and media should be used to identify <em>Shigella. <\/em>These findings were recently published in <em><a href=\"https:\/\/doi.org\/10.1093\/infdis\/jiaf630\"><strong>The Journal Of Infectious Diseases<\/strong><\/a><\/em> and <em><a href=\"https:\/\/pubmed-ncbi-nlm-nih-gov.offcampus.lib.washington.edu\/41746130\/\"><strong>Journal of Clinical Microbiology<\/strong><\/a><\/em><strong>.<\/strong><\/p>\n<p>The message is clear: <em>Shigella<\/em> is placing an unacceptable burden on young children, and rising resistance is rapidly eroding the tools available to treat <em>Shigella<\/em> diarrhea. These findings strongly point to the demand for investment in vaccines and other lifesaving interventions to protect the world\u2019s most vulnerable children.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Enterics for Global Health (EFGH) study, funded by the Gates Foundation, has found that Shigella\u2014a leading cause of childhood diarrhea worldwide\u2014poses a far greater threat than previously described. The study documents both a substantial disease burden in young children and rapidly increasing resistance to commonly used, and recommended, antibiotics. These findings, now published by&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/globalwach\/2026\/03\/24\/primary-results-of-the-enterics-for-global-health-efgh-study-on-shigella-burden-and-antibiotic-resistance-in-children-published-in-the-lancet-global-health\/\">Read more<\/a><\/div>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86,94,16],"tags":[],"class_list":["post-18449","post","type-post","status-publish","format-standard","hentry","category-gut-health-and-child-survival","category-publication","category-research"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/posts\/18449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/comments?post=18449"}],"version-history":[{"count":10,"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/posts\/18449\/revisions"}],"predecessor-version":[{"id":18789,"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/posts\/18449\/revisions\/18789"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/media?parent=18449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/categories?post=18449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/globalwach\/wp-json\/wp\/v2\/tags?post=18449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}